Allan Shulkin, MD
Pulmonary Disease · Dallas, TXNPI 1174566160
Payments from drug & device makers
Across 11 payments — averaging $292.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Pharming Healthcare, Inc.$52
- Merck$13
- Veran Medical Technologies, Inc.$9
What the payments were for
- Travel & lodging$60%
- Food & beverage$1475%
- Education$3,06595%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $3,144 |
| Pharming Healthcare, Inc. | 2 | $52 |
| Merck | 1 | $13 |
| Veran Medical Technologies, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,000
How this compares
$3,218 in reported general payments places this provider in the 50th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 220 | $176,749 |
| EliquisApixaban | 75 | $52,711 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $50,823 |
| Breo ElliptaFluticasone/Vilanterol | 70 | $26,961 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $11,621 |
| Qvar RedihalerBeclomethasone Dipropionate | 18 | $9,361 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,613 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $4,426 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 99 | $2,672 |
| Azithromycin | 217 | $2,093 |
| Prednisone | 315 | $1,942 |
| Wixela InhubFluticasone Propion/Salmeterol | 26 | $1,544 |
| PaxlovidNirmatrelvir/Ritonavir | 15 | $1,429 |
| Famotidine | 162 | $1,148 |
| Montelukast Sodium | 108 | $922 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Dallas
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Trushil ShahDallas$1.4M
- Yolanda MagetoDallas$1.4M
- Mark MillardDallas$1.2M
- Chetan NaikDallas$678K
- Craig GlazerDallas$469K
- Yosafe WakwayaDallas$439K
- Sonja BartolomeDallas$423K
- Corey KershawDallas$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.